Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Chest MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The international thoracic organ transplant Registry of the international Society for heart and lung transplantation: Thirty-eighth adult lung transplantation report- 2021; focus on recipient characteristics.J Heart Lung Transpl. 2021; 40: 1060-1072
- The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation.Am J Transpl. 2015; 15: 3024-3040
- Comprehensive care of the lung transplant patient.Chest. 2017; 152: 150-164
- Survival in adult lung transplantation: where are we in 2020?.Curr Opin Organ Transpl. 2020; 25: 268-273
- Long-term outcomes and management of lung transplant recipients.Best Pract Res Clin Anaesthesiol. 2017; 31: 285-297
- Recipient screening prior to solid-organ transplantation.Clin Infect Dis. 2002; 35: 1513-1519
- Infectious complications in lung transplant Recipients.Lung. 2020; 198: 879-887
- Screening of donor and candidate prior to solid organ transplantation- guidelines from the American Society of transplantation infectious diseases community of practice.Clin Transpl. 2019; 33: e13548
- Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of transplantation infectious diseases community of practice.Clin Transpl. 2019; 33: e13563
- Donor-derived infections: guidelines from the American Society of transplantation infectious diseases community of practice.Clin Transpl. 2019; 33: e13547
- Infection in organ transplantation.Am J Transpl. 2017; 17: 856-879
- Diagnosis and outcome of early pleural space infection following lung transplantation.Chest. 2009; 135: 484-491
- Infections in solid organ transplant recipients.N Engl J Med. 2007; 357: 2606-2614
- Viral infections in lung transplantation.J Thorac Dis. 2021; 13: 6673-6694
- Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004.Clin Infect Dis. 2010; 50: 1439-1447
- Cytomegalovirus in solid organ transplant recipients.Am J Transpl. 2009; 9: S78-S86
- Cytomegalovirus and lung transplantation.Am J Transpl. 2004; 4: 1219-1226
- The indirect effects of cytomegalovirus infection on the outcome of organ transplantation.JAMA. 1989; 261: 3607-3609
- Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting.Transpl Infect Dis. 2017; 19: 1-11
- Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant pateints.Transpl Infect Dis. 1999; 1: 157-164
- Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.Am J Respir Crit Care Med. 2010; 181: 1391-1396
- Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome.Am J Transpl. 2011; 11: 2190-2196
- Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment.Transplantation. 2014; 98: 1013-1018
- Cytomegalovirus infection and survival in lung transplant recipients.J Heart Lung Trnasplant. 1991; 10: 638
- Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.Transplantation. 2005; 80: 157
- Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of transplantation infectious diseases community of practice.Clin Transpl. 2019; 33: e13512
- Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid organ transplant recipients: a multicenter cohort study.Clin Infec Dis. 2013; 56: 817-824
- Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.Transpl Infect Dis. 2013; 15: 163-170
- Controversies in lung transplantation: management of cytomegalovirus infections.J Heart Lung Transpl. 2002; 21: 841
- Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.Clin Infect Dis. 2008; 46: 831-839
- Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.Transpl Infect Dis. 2018; 20: e12893
- Definitions of cytomegalovirus infection and disease in transplant patients for Use in clinical trials.Clin Infect Dis. 2017; 64: 87-91
- Cytomegalovirus pneumonia in transplant patients: CT findings.J Comput Assist Tomogr. 1996; 20: 295-299
- The third international Consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.Transplantation. 2018; 102: 900-931
- Lung transplant pathology. A comparative study of pulmonary acute rejection and cytomegalovirus infection.Am J Surg Pathol. 1991; 15: 1197-1201
- Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry.J Clin Microbiol. 2004 May; 42: 2168-2172
- Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients.Chest. 2000; 118: 1653-1660
- Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipeints.J Infect Dis. 2004; 190: 1076-1083
- Cytomegalovirus viral load in bronchoalveolar lavage to diagnose lung transplant associated CMV pneumonia.Transplantation. 2018; 102: 326-332
- Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients.Am J Transpl. 2013; 13: 2402-2410
- Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.Ann Intern Med. 2010; 152: 761-769
- Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.Am J Transpl. 2004; 4: 611-620
- Association of CMV-specific T-cell immunity and risk of CMV infection in lung transplant recipients.Clin Transpl Jun. 2021; 35: e14294
- Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation.Am J Transpl Jun. 2005; 5: 1483-1489
- Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial.BMJ Open. 2019; 9: e030648
- Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events.BMC Infect Dis. 2020; 20: 58
- Maribavir, brincidofovir, and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.Med Mal Infect. 2018; 48: 495-502
- Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.Am J Transpl. 2018; 18: 3060-3064
- Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.Transpl Infect Dis. 2019; 21: e13166
- Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipeints.Transplantation. 2020; 104: 410-414
- Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.Am J Transpl. 2007; 7: 2106-2113
- Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.Am J Transpl. 2009; 9: 1205-1213
- Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients.Clin Infect Dis. 2017; 65: 57-63
- Risk factors for failure of primary valganciclovir prophylaxis against cytomegalovirus infection and disease in solid organ transplant recipients.Open Forum Infect Dis. 2019; 6: ofz215
- Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Clin Infect Dis. 2013; 56: 1018
- Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: a single-center study.Transpl Infect Dis. 2018; 20: e12852
- Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.Rev Med Virol. 2008; 18: 233-246
- Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind phase 2 study.Clin Infect Dis. 2019; 68: 1255-1264
- Overview: cytomegalovirus and the herpesviruses in transplantation.Am J Transpl. 2013; 13 (quiz 8): 1-8
- Preventive strategies against cytomegalovirus and incidence of alpha-herpesvirus infections in solid organ transplant recipients: a nationwide cohort study.Am J Transpl. 2017; 17: 1813-1822
- Varicella zoster virus and herpes simplex virus in solid organ transplant patients.AM J Transpl. 2013; 13 (quiz 66): 55-66
- Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era.Am J Transpl. 2004; 4: 108-115
- Incidence and clinical characteristics of herpes zoster after lung transplantation.J Jeart Lung Transpl. 2008; 27: 11-16
- A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients.Transplantation. 2010; 89: 1028-1033
- Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies.Am J Transpl. 2011; 11: 1071-1078
- Community acquired respiratory viral infection in adult lung transplant recipients.Chest. 1998; 113: 944-950
- A single-season prospective study of respiratory viral infections in lung transplant recipients.Eur Respir J. 2006; 28: 131-137
- Respiratory virus in bronchoalveolar lavage: a hospital based cohort study in adults.Thorax. 2009; 64: 399-404
- Respiratory viral infections in immunocompetent and immunocompromised persons.Am J Med. 1997; 102 (discussion 25-6): 2-9
- Imaging of pulmonary viral pneumonia.Radiology. 2011; 260: 18-39
- Respiratory viral infections in transplant recipients.Antivir Ther. 2007; 12: 627-638
- Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling.J Clin Microbiol. 2009; 47: 3439-3443
- Outcomes from pandemic influenza A H1N1 infection in recipients of solid organ transplants: a multicenter cohort study.Lancet Infect Dis. 2010; 10: 521-526
- A 5-year prospective multicenter evaluation of influenza infection in transplant recipients.Clin Infect Dis. 2018; 67: 1322-1329
- Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study.Thorax. 2014; 69: 32-38
- Nucleic acid amplification-based diagnosis of respiratory virus infections.Expert Rev Anti Infect Ther. 2010 Nov; 8: 1273-1292
- The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients.J Clin Virol. 2002; 25: 171-175
- Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults.J Clin Microbiol. 1996 Jul; 34: 1649-1653
- RNA respiratory viruses in solid organ transplantation.Am J Transpl. 2013; 13: 212-219
- Chemokines, their receptors, and transplant outcome.Transplantation. 2002; 74: 149-155
- Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus.J Infect Dis. 1999; 180: 10-14
- Interleukin-8, interleukin-6, and soluble tumor necrosis factor receptor type 1 release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus.Immunology. 1994; 82: 126-133
- Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, indueced by influenza virus A.J Allergy Clin Immunol. 1996; 98: 1080-1087
- Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.J Immunol. 2002; 169: 1037-1049
- Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection.J Immunol. 2003; 171: 4844-4852
- CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction.Am J Transpl. 2012 Feb; 12: 477-484
- Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients.Clin Infect Dis. 2010; 51: 163-170
- Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study.Am J Trnasplant. 2017; 17: 1304-1312
- Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction.Clin Infect Dis. 2019; 69: 1192-1197
- Graft loss and CLAD-onset is hastened by viral pneumonia after lung transplantation.Transplantation. 2016; 100: 2424-2431
- Viral respiratory tract infection during the first postoperative year is a risk factor for chronic rejection after lung transplantation.Transpl Direct. 2018; 4: e370
- Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death.Am J Respir Crit Care Med. 2004; 170: 181-187
- Symptomatic respiratory virus infection and chronic lung allograft dysfunction.Clin Infect Dis. 2016; 62: 313-319
- Respiratory viruses and chronic rejection in lung transplant recipeints.J Heart Lung Transpl. 2002; 21: 559-566
- Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection- myth or reality?.Am J Transpl. 2003; 3: 245-249
- Community-acquired respiratory viruses post-lung transplant.Semin Respir Crit Care Med. 2021; 42: 449-459
- Influenza virus infection in adult solid organ transplant recipients.Am J Transpl. 2002 Mar; 2: 287-291
- Anti-influenza therapy: the emerging challenge of resistance.Therapy. 2009; 6: 883
- Adenovirus infections in transplant recipients.Clin Infect Dis. 2006; 43: 331-339
- AST infectious diseases community of practice. Adenovirus in solid organ transplant recipients. Guidelines from the American Society of transplantation infectious diseases community of practice.Clin Transpl. 2019; 33: e13527
- Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.J Heart Lung Transpl. 2003; 22: 745-753
- Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus.Am J Respir Crit Care Med. 2008; 178: 876-881
- Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection.J Heart Lung Trasnplant. 2009; 28: 67-71
- Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency.J Heart Lung Transpl. 2015; 34: 958-962
- Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin.J Heart Lung Transpl. 2007; 26: 862-864
- Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients.Transplantation. 2002; 73: 1075-1078
- Respiratory syncytial virus and parainfluenza virus.N Engl J Med. 2001; 344: 1917-1928
- A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.Transpl Infect Dis. 2010; 12: 38-44
- Fungal infection in lung transplantation.Semin Respir Crit Care Med. 2021; 42: 471-482
- Invasive mold infections in lung and heart-lung transplant recipients: Stanford University Experience.Transpl Infect Dis. 2015; 17: 259-266
- Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.Am J Transpl. 2009; 9: 1903-1911
- Invasive pulmonary Aspergillosis in organ transplants- Focus on lung transplants.Respir Investig. 2016; 54: 76-84
- Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: as 12-year experience.Infection. 2017; 45: 867-875
- Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis.Clin Infect Dis. 2006; 42: 1417-1427
- Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of transplantation infectious disease community of practice.Clin Transpl. 2019; 33: e13544
- Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary asspergillosis in patients with hematologic malignancies.Chest. 2010; 137: 410-415
- Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanlysis and systematic review.Chest. 2010; 138: 817-824
- Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases- the role of factors affecting assay performance.Int J Infect Dis. 2011; 15: e874-e881
- Application of the 1,3-B-D-Glucan (Fungitell) assay in the diagnosis of invasive fungal infections.Arch Pathol Lab Med. 2016; 140: 181-185
- Antifungal prophylaxis in lung transplant recipients.Transplantation. 2016 Sep; 100: 1815-1826
- Invasive fungal infection after lung transplantation: epidemiology in the setting of antigunfal prophylaxis.Clin Infect Dis. 2020; 70: 30-39
- Variation in antifungal prophylaxis strategies in lung transplantation.Transpl Infect Dis. 2006; 8: 213-218
- Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey.Transpl Infect Dis. 2015; 17: 14-20
- Aspergillus fumigatus invasion increases with progressive airway ischemia.PLOS One. 2013; 8: e77136
- Pulmonary infection defense after lung transplantation: does airway ischemia play a role?.Curr Opin Organ Transpl. 2010; 15: 568-571
- Risk factors of invasive fungal infections in lung transplant recipients: a systematic review and meta-analysis.J Heart Lung Transpl. 2022; 41: 255-262
- Strategies for the prevention of invasive fungal infections after lung transplant.J Fungi (Basel). 2021; 7: 122
- Infection prophylaxis and management of fungal infections in lung transplant.Ann Transl Med. 2020; 8: 414
- Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infection following lung transplantation.Transpl Infect Dis. 2021; 23: e13448
- Isavuconazole is as effective as and better Tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients.Clin Infect Dis. 2021; 73: 416-426
- Comment: invasive fungal infections in lung transplant recipients.Clin Infect Dis. 2021; 72: 365-366
- Antifungal prophylaxis in adult lung transplant recipients: Uncertainty despite 30 years of experience. A systematic review of the literature and network meta-analysis.Transpl Infect Dis. 2022; 24: e13832
- Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management.J Heart Lung Transpl. 2003; 22: 258-266
- Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies.Transpl Infect Dis. 2001; 3: 161-167
- Clinical risk factors for invasive aspergillosis in lung transplant recipients: results of an international cohort study.J Heart Lung Transpl. 2018; 37: 1226-1234
- Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients.Chest. 2003; 123: 800-808
- Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America.Clin Infect Dis. 2016; 63: e1-e60
- Epidemiology of candidemia in lung transplant recipeints and risk factors for candidemia in the early posttransplant period in the absence of universal antifungal prophylaxis.Transpl Infect Dis. 2022; 24: e13812
- Epidemiology and Outcome of Zygomycosis: a review of 929 reported cases.Clin Infect Dis. 2005; 41: 634-653
- Epidemiology of Cryptococcosis and Cryptococcal meningitis in a large retrospective cohort of patients after solid organ transplantation.Open Forum Infect Dis. 2017; 4: ofx004
- An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients.Clin Infect Dis. 2005; 40: 1756-1761
- Fusarium infection in lung ttransplant patients: report of 6 cases and review of the literature.Medicine (Baltimore). 2011; 90: 69-80
- Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome.Clin Infect Dis. 2002; 34: 1098-1107
- Should prophylaxis for Pneuocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?.Clin Infect Dis. 1999; 28: 240-246
- Pneumocystis pneumonia.N Engl J Med. 2004; 350: 2487-2498
- AST infectious diseases community of practice. Endemic fungal infections in solid organ transplant recipients- guidelines from the American Society of transplantation infectious diseases community of practice.Clin Transpl. 2019; 33: e13553
- Mycobacteria: selection of transplant candidates and post-lung transplant outcomes.Semin Respir Crit Care Med. 2021 Jun; 42: 460-470
- Practical guidance for clinical microbiology laboratories: mycobacteria.Clin Microbiol Rev. 2018; 31: e00038
- Donor derived Mycobacterial tuberculosis infection after solid-organ transplantation: a comprehensive review.Transpl Infect Dis. 2018; 20: e12971
- Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2000 cases.Clin Transpl. 2018; 32: e13259
- Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation.Clin Transpl. 2019; 33: e13513
- Tuberculosis in solid organ transplant candidates and recipients: current and future challenges.Curr Opin Infect Dis. 2014 Aug; 27: 316-321
- Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation.J Heart Lung Transpl. 2021; 40: 1349-1379
- Spanish Network for Research in Infectious Diseases. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort.Clin Infect Dis. 2009; 48: 1657-1665
- Official American thoracic Society/centers for disease control and prevention/infectious diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis.Clin Infect Dis. 2016; 63: e147-e195
- AST infectious diseases community of practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients- guidelines from the American Society of transplantation infectious diseases community of practice.Clin Transpl. 2019; 33: e13588
- The spectrum of mycobacterial infection after lung transplantation.Am J Respir Crit Care Med. 1999; 160: 1611-1616
- Nontuberculous mycobacterial infections in solid organ transplantation.Am J Transpl. 2013; 13: 77-82
- Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/SCMID/IDSA clinical practice guideline.Clin Infect Dis. 2020; 71: e1-e36
- Outcomes in lung transplant recipeints with Mycobacterium abscessus infection: a 15-year experience from a large tertiary care center.Transpl Proc. 2019; 51: 2035-2042
- Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: a single center experience.Transpl Infect Dis. 2019; 21: e13084
- Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients.Int J Mol Sci. 2019; 20: E5868
- Nontuberculous mycobacteria in cystic fibrosis.Semin Respir Crit Care Med. 2018; 39: 383-391
- Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study.Transpl Infect Dis. 2012; 14: 452-460
- Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.Thorax. 2006; 61: 507-513
- Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients.Clin Infect Dis. 2004; 38: 1428-1439
- ATS Mycobacterial Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.Am J Respir Crit Care Med. 2007; 175: 367-416
- Bacteriophage therapy as a treatment option for transplant infections.Curr Opin Infect Dis. 2020; 33: 298-303
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
